Healius share price on watch as FY20 results hit guidance

The Healius Ltd (ASX: HLS) share price is on watch as COVID-19 boosted pathology earnings but the board scrapped its final dividend

The Healius Ltd (ASX: HLS) share price is one to watch today after the Aussie healthcare group reported full-year results in line with guidance.

changing asx share price represented by hand arranging wooden blocks that spell update

Image source: Getty Images

Why is the Healius share price worth watching?

For the year ended 30 June 2020 (FY20), Healius reported a 2.2% increase in underlying revenue to $1,600.4 million.

Underlying earnings before interest and tax (EBIT) fell 18.4% lower to $102.7 million. That saw underlying net profit after tax (NPAT) from continuing operations fall 21.2% lower to $55.4 million.

Both of these figures were in line with Healius' 27 July 2020 trading update with underlying NPAT in line with its mid-March guidance.

The coronavirus pandemic did weigh on earnings but strong pathology trading and subsequent initiatives underpinned the result. That strong pathology performance was aided by COVID-19 testing which is increasing in FY21.

Healius also booked a $142.5 million loss relating to the in-year impart of its Healius Primary Care business, largely relating to goodwill.

The company also reported strong performance up to March 2020 across its Pathology, Imaging and Montserrat Day Hospitals.

FY20 operating cash flow was up on FY19 figures to $153.4 million despite COVID-19. That saw the company's net debt position improve to $666 million with $424 million in liquidity.

What's happening with the final dividend?

Despite some strong earnings, the board declined to pay a full-year dividend. That makes the Healius share price worth watching as investors consider the capital management decision.

The first half dividend of 2.6 cents per share has been delayed due to COVID-19 until October.

Healius decided it was "not considered appropriate" given the assistance received. That includes significant government support, with other ASX companies coming under pressure this August.

An out-of-cycle dividend will be considered as part of a capital structure review following the Healius Primary Care sale.

Trading update

In a good sign for the Healius share price, the company reported a strong start to FY21.

Pathology revenues were up by 25% in July compared to last year thanks to significant community COVID-19 testing. Pathology has commercial contracts for COVID-19 screening with entities like the Federal Government and the AFL.

Imaging revenues were down 4% from July 2019 with further declines in August. Day Hospital has started the year strongly with Montserrat revenue up 27% compared to July 2019 and Adora Fertility up more than 50%.

Healius Primary Care revenues were up 7.5% on pcp with the dental business now recording results to receive the earn-out on completion of the Healius Primary Care sale.

Outlook

Management did cite a "strong outlook" for FY21 largely underpinned by the pathology business.

The board expects regular dividends to recommence in the first half of next year which is good news for the Healius share price.

Healius will provide a further trading update on 22 October when it holds its annual general meeting.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »